Semaglutide vs Liraglutide: Weight Loss, Side Effects and Cost

Semaglutide produced more weight loss than liraglutide in STEP 8, a direct randomized trial in adults with overweight or obesity without diabetes. Mean weight change at 68 weeks was −15.8% with weekly semaglutide and −6.4% with daily liraglutide. Both groups also received diet and physical-activity counseling¹.

That answers an important question, but not every question involved in choosing care. The comparison depends on the preparation, indication, tolerability and price you can actually obtain. It does not mean that an arbitrary semaglutide vial has been tested against an arbitrary liraglutide prescription, or that someone doing well on liraglutide should automatically switch.

What STEP 8 compared

The study enrolled 338 adults and compared subcutaneous semaglutide 2.4 mg once weekly with liraglutide 3.0 mg once daily, with matched placebo groups. The active-drug comparison was open-label: people knew which active medication they received. That matters when interpreting preferences or symptoms, even though measured weight is a relatively concrete outcome¹.

The doses describe the trial, not an instruction to start treatment at those amounts. Each drug was escalated over time. Participants' eligibility, follow-up and accompanying lifestyle support also belong with the results. Removing those conditions turns a clinical finding into a sales promise.

STEP 8 studied injections. It did not compare oral semaglutide with liraglutide, establish a tablet-to-pen conversion or test a compounded blend. Our oral weight-loss peptide guide explains why the delivery system is a separate scientific question. A matching ingredient name does not erase that difference.

How large was the benefit?

The difference between the groups was 9.4 percentage points of starting body weight. That is a difference in percentages, not 9.4 pounds and not a claim that every participant lost the same amount. For an individual deciding whether treatment meets a health goal, the distribution of responses matters alongside the average.

A larger fraction of semaglutide participants reached the trial's 10%, 15% and 20% weight-loss thresholds. The results therefore favor semaglutide across more than one way of describing weight change. They still do not predict an individual's response or prove that the largest possible weight reduction is the right goal for every reader¹.

Liraglutide also has its own placebo-controlled evidence. In SCALE, 3,731 adults without type 2 diabetes were followed for 56 weeks; average weight loss was 8.4 kg with liraglutide and 2.8 kg with placebo². That finding establishes activity against placebo. Comparing those kilograms directly with another trial's percentages would be a poor substitute for STEP 8.

Weekly versus daily injections

The trial compared weekly semaglutide with daily liraglutide. For some people, fewer injection days may be convenient. For others, coverage, familiarity with a device or the practical ability to continue treatment may matter more. Convenience is a preference to discuss, not a measured guarantee of adherence.

The current Wegovy and Saxenda prescribing information should guide the particular product's administration, missed-dose instructions and escalation. Do not carry instructions from one pen into the other, and do not use the number printed on a dose dial as an equivalence between molecules³⁴.

Bring the actual product name to the appointment. Semaglutide and liraglutide each appear in products with different approved purposes. A comparison of obesity-treatment regimens should not quietly substitute a diabetes dose simply because it uses the same active ingredient. Our semaglutide dosage guide keeps brand, dose and syringe units separate.

Is liraglutide easier on the stomach?

STEP 8 does not support a simple claim that daily liraglutide avoids gastrointestinal effects. At least one gastrointestinal adverse event was reported by 84.1% of semaglutide participants and 82.7% of liraglutide participants over the study. Those figures count events across follow-up; they do not mean that everyone was nauseated every day¹.

The way a person tolerates one medication cannot be read from the average response to another. Ask which symptoms are expected, how to contact the prescribing team and what would prompt a treatment review. Persistent vomiting or severe abdominal pain should not be treated as proof that a weight-loss drug is working especially well.

The broader semaglutide trial analysis is useful here: most of the drug's additional weight loss was independent of gastrointestinal adverse events⁵. Feeling sick is not the desired mechanism of success. Our GLP-1 nausea guide explains that distinction without equating ordinary symptoms with an emergency.

Stopping treatment is a separate outcome

In STEP 8, discontinuation for any reason was less frequent with semaglutide than liraglutide. However, the protocols differed in what happened when participants could not tolerate the target dose. That detail limits an overly broad claim that one drug is always easier to stay on¹.

When reviewing an online comparison, check whether a dropout number means stopping for an adverse event, stopping for any reason or failing to attend the final visit. Those are different outcomes. A page that switches between them without explanation can make a real study look more decisive than it was.

Continuity also changes the financial comparison. A lower monthly quote has limited value if the medication cannot be obtained consistently or follow-up is inaccessible. Ask about the clinical plan for interruptions before they happen. Our weight-regain review addresses what withdrawal trials show, while keeping that question separate from the initial drug choice.

How to compare cost honestly

There is no single universal semaglutide-versus-liraglutide price. Insurance eligibility, the exact branded or compounded preparation, pharmacy supply, visit fees and ongoing membership charges can change what a patient pays. A trial's average efficacy does not establish the least expensive option under your insurance plan.

Request a written estimate for the same treatment period. Clarify whether the quote includes medication, prescribing visits, necessary follow-up, shipping and any recurring fee. Ask whether it is an introductory price and what changes if the dose changes. Our semaglutide cost guide and price transparency index provide a framework for reading these quotes.

A compounded preparation is not an FDA-approved generic substitute simply because a seller uses that language. FDA states that compounded GLP-1 drugs do not undergo its premarket review for safety, effectiveness and quality⁶. Identify the dispensing pharmacy and discuss why a compounded medication is being proposed rather than treating every cheaper offer as an equivalent product.

For service details, compare the documented terms in our Ro review and Hims membership and medication charges. The WeightWatchers Clinic pricing structure and Found review offer additional care-model comparisons. These are provider reviews, not evidence that any service currently offers both drugs or is appropriate for your medical history.

What an active person should ask

For a reader who trains, the relevant outcome includes maintaining food intake, strength and recovery while weight changes. A larger average weight reduction does not establish that one drug preserves more muscle in an athlete. STEP 8 was not a performance or muscle-preservation trial.

Bring a realistic account of current training, meal tolerance and injury limitations. If appetite suppression makes regular meals difficult, ask how the plan will be adjusted. Do not assume that adding an experimental recovery peptide solves a nutrition or tolerability problem. Our GLP-1 muscle-loss article separates lean-mass measurements from actual strength outcomes.

A clinician may weigh existing disease, other medications, contraindications, pregnancy plans and prior adverse effects more heavily than the group mean in a weight-loss trial. These details are reasons to individualize the choice, not exceptions that invalidate the trial. Good evidence narrows the discussion without replacing it.

Contraindications are not a popularity contest

Both product labels contain a boxed warning concerning thyroid C-cell tumors and contraindications involving a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The human relevance of the rodent tumor findings is not established³⁴. Neither a higher weight-loss average nor a lower price overrides the need to screen the actual patient.

This is a specific history question, not a statement that every thyroid condition is the same. Tell the prescriber the diagnosis rather than checking a broad thyroid box and assuming it settles eligibility. Also provide previous serious drug reactions, relevant gastrointestinal disease and pregnancy plans. If you do not know a family diagnosis, say so rather than inventing certainty on an intake form.

A trial comparison cannot resolve every such history. Ask which finding would rule a product out, which calls for additional evaluation and who will coordinate that evaluation. That is more useful than choosing whichever drug an advertisement calls safer.

Read a price comparison as a dated offer

Consider two hypothetical quotes: one includes medication and follow-up, while another lists a membership charge before medication is added. Those are different packages even if the larger number initially looks more expensive. The example is a way to compare the structure, not a claim about any provider's current price.

Ask how many days of treatment the quote represents and whether the included medication matches the product you discussed with the clinician. A four-week supply, a calendar month and an annual prepayment should not be compared without adjusting the time period. Also clarify what happens financially if the clinician decides that neither medicine is appropriate.

A cancellation policy, insurance-assistance service or introductory offer may affect practical access without changing the drug's measured efficacy. Keep those commercial facts beside the clinical comparison, with each labeled for what it establishes. The result should be a choice you can explain in terms of medical fit, expected benefit and a sustainable way to obtain care.

Does semaglutide make liraglutide obsolete?

No single trial can answer that for every patient. STEP 8 makes the average weight-loss comparison unusually clear, but it did not randomize people by their insurance coverage, test every available product or ask whether stable liraglutide users should switch.

If you are already using liraglutide successfully, define what a switch is meant to improve: a specific health outcome, tolerability, access or cost. Ask what would count as success and what the follow-up plan would be. Changing drugs because a headline quotes a larger percentage is less useful than changing for a concrete clinical reason.

If you have never used either medication, discuss the exact product and the support needed to use it safely. If the question has moved to tirzepatide, our tirzepatide-versus-semaglutide comparison covers that different evidence base. The most defensible conclusion here is specific: in STEP 8's population and regimens, injectable semaglutide produced substantially greater average weight loss than injectable liraglutide.